ifox, Author at Small Cap Exclusive

Global Consortium Inc. (OTCMKTS:GCGX) Negotiates A revised 5-year lease of Sacramento Building with Option to Buy

The shares of Global Consortium Inc. (OTCMKTS:GCGX) continues to move higher and gains another 6% in Wednesday’s session. The stock has gained about 70% over the past month. Here are some of the key developments.

Last week, Global Consortium reviewed terms of its lease of the building it currently leases in Sacramento with the option of acquiring 25,000 sq. ft. of the building. The company seeks to secure the First Right of Refusal of the 39,000 sq. ft. of the remaining section of the facility.

Global to Acquire the Sacramento Building They Lease

The revised lease and the acquisition deal will involve the company and the owner of the building. With Global leasing a larger section of the facility, they have the opportunity of multiplying sections of the business operations before acquiring the building.

The company intends to use 5,000 sq. ft. for manufacturing operations of Infused Edibles and Indulge Oils and also for white Label contracts. They will also allocate 5,000 sq. ft. for distribution and delivery likely to be running before the end of this year. The rest of the space will go into house cultivation as well as more manufacturing opportunities.

Final Inspection of the Sacramento Facility

A few weeks ago the company reported significant progress in the reading workspace in Sacramento. With the positive progress, operations are ready to commence in September. Since the issuance of the permit, the City has been to the facility on several occasions in the last 10 weeks. They have so far carried inspection on rebar, plumbing, fire sprinklers, and concrete inside and out.

The installed the CO2 exhaust system in the last week of August and they are waiting for other inspections. Inspections expected include CO2 Exhaust, CO2 System, Building Code, ADA, Asphalt, Electrical and Cannabis Manufacturing & Agricultural.

The company anticipated the space to be completed by the end of August in readiness for assessment. Global expects final inspection in early September after which they will receive a Certificate of Occupancy following the passing of the final inspection. With the issuance of the Certificate of Occupancy, Indulge Oils will commence the manufacture of THC products for sales. There are plans to start moving Infused Edibles into the facility to begin processing and production of THC infused products.

Rainmaker Worldwide (RAKR) Soars 1000% in a Week: Banking on the Water Crisis Management

Rainmaker Worldwide (OTCMKTS:RAKR) is the biggest penny stock gainer this week as investors started noticing solid potentials. The stock has soared 165% over the past 3-session on hefty volume. In fact, the stock has soared as much as 1025% over the past one week from $0.008 to $0.009.

As everyone knows, the water crisis is now a real issue in many parts of the world and many experts believe that it is going to grow more acute in the years to come. Hence, it is only natural for some companies to have entered this space in a big way. One of those companies is Canada based Rainmaker Worldwide (OTCMKTS:RAKR), which is involved in providing drinking water solutions in a range of geographies. According to the company’s own website, it wishes to make “drinking water possible in impossible places”. It is a business that is noble and at the same time, there is potential to grow significantly in the coming years.

Business Analysis

The company’s main purpose is to provide safe drinking water to people in different parts of the world. Considering the fact that freshwater availability is highly skewed, there are many areas in the Middle East, Africa, and India among others, where safe drinking water is not available. Rainmaker wishes to change that and in order to do so, it uses two types of technology. One of those is air to water and the other is water to water. Using these two technologies, the company produces drinking water that is safe for everyone.

Rainmaker is led by a highly experienced and efficient executive team. Michael O’Connor is the CEO, Chairman of the board and also a director of the company. Having been an executive at Orascom Telecom in Egypt, O’Connor helped spread the company’s mobile connections millions of people in 10 nations. The other key executives are Paul H. Heney, who is the Vice President of the company’s operations in Asia and Joost Oosterling, who is in charge of the European operations.

The water crisis is already at alarming levels and at this point in time, as many as 5 billion people experience water scarcity every month on an average. Since the population of the world is going to continue to grow, the water crisis is only going to get worse at a global level and that is where the expertise of a company like Rainmaker is so important. Rainmaker is also uniquely positioned as the crisis unfolds. The company uses its superior technology to deliver water locally in 5000 liters to 150000 liters units. Local delivery means that the company is not bogged down by red tape in overseas locations and that makes it a significantly attractive investment opportunity.

Puration Inc (PURA) Stock Soars 17% After CBD Beverage Survey

Puration, Inc. (PURA)’s shares had a solid day as the stock soared as much as 17% to close at $0.055. What is more interesting is that Wednesday’s volume was the highest in the past 3-month.

On Wednesday, Puration Inc announced the results of the CBD-infused beverage market research carried out by Goldman Small Cap Research. The market survey is part of the company’s pre-marketing campaign for its new CBD infused coffee, tea, and beer beverages.

CBD infused tea preferable

Results show that tea is the most preferable CBD beverage for consumers and the main reason consumers take CBD is to manage anxiety. Majority of users despite age or geographic diversity consumed CBD products to treat inflammation and relieve anxiety.

Puration is already a leading company in the CBD-infused beverage segment and it produced more than $1 million in CBD beverages in the US last year. In the first half of 2019, the company has already reported $1 million in sales of CBD beverages. Puration has a target of around $4 million sales this year.

The company has indicated that Goldman Small Cap Research has confirmed a speculative buy and PPS target of $0.25 for the company following the results of the market survey. The research firm indicated that Puration is a better positioned CBD-infused beverage provider. Their popular CBD-infused energy water has sold millions worth of beverages in 2019. The expansion to the anti-inflammatory and anti-anxiety characteristics of the popular CBD-infused tea makes leaves most of the key bases covered for Puration.

Puration partners with beer producer to produce CBD Infused beer

Recently the company implemented a program to introduce CBD-infused forms of the current third-party beverages. The company has partnered with a beer producer to produce CBD-infused beer the same way it has partnered with a tea producer and coffee producer to produce CBD infused tea and coffee.

The company recently made a presentation on its CBD infused beverage initiatives on its website. The management is planning to updates the company’s coffee, tea, and beer strategy in combination with the market survey results.

The data collected from the survey will be vital in targeting the company’s marketing path for CBD infused beverages. The company currently racks millions in sales from its EVERx CBD Sports Water.

Why Gratitude Health (OTCQB:GRTD) Stock Soared A Whooping 87%

Sometimes some stocks start rising dramatically despite no news with regards to the company’s business and that is what happened with the Gratitude Health (OTCQB:GRTD) stock on Tuesday. The company is involved in making and marketing beverages that are meant for nutrition as well as for healthy aging.

Gratitude Health

On Tuesday, the stock jumped by as much as 87% and emerged as one of the highest gainers in the market on the day. Since there is no news with regards to the company that could have triggered this rise, it is perhaps worthwhile to take a closer look at the company.

[thrive_leads id=’8276′]

Interesting Analysis

The company has taken massive strides over the course of 2019 and that could also be the reason behind the sudden rally in the Gratitude Health stock on Tuesday. In January, the company had launched the first-ever ketogenic meal replacement beverage in the world and it is a product that could eventually prove to be a revolutionary one. At the time, the company had announced that the launch was going to take place in the second quarter of this year. The product is going to made available in three separate flavors and if the sales of this product do manage to show strong demand, then it could be a huge positive for the company.

However, that is not all. Earlier on in August, it had emerged that the Gratitude Health’s beverages had been taken on by Duane Reade by Walgreens as part of a pilot project named the ‘healthy set’ platform. It is a significant development for the company and one that could propel it into bigger things in the future. However, it is also necessary to keep in mind that Gratitude’s products are already being distributed by as many as 200 stores spread across Connecticut, New Jersey, and New York. The whole distribution process is managed by the company’s partner Dora Naturals.

Puradyn Filter Technologies (OTCMKTS:PFTI) Stock Jumps Days After reporting Quarterly Results

Puradyn Filter Technologies Incorporated (OTCMKTS:PFTI) was one of the biggest gainers in Tuesday’s session without any news. Recently, the company announced its financial results for the second quarter of 2019.

Q2 2019 Revenue Results

The company reported a 59% decrease in net sales from around $1.15 million in Q2 2018 to around $468,525. Equally net sales in the first half of the year declined 53% from $around $2.04 million last year to $951, 518. The decline in sales was mainly attributed to some delays in customer orders because of the rapid decline in market certainty. The drop is also a result of the volatility of oil prices in the market especially in the gas and oil segment which began late last year and continued to the just-ended quarter.

Puradyn reported a net loss of $361,528 or $0.01 per share in the quarter relative to net income of $8,872 or $0.00 per share in Q2 2018.

[thrive_leads id=’8276′]

The CEO of Puradyn, Ed Vittoria, indicated the Q2 results were hit by delays of expected orders from current and prospective customers in the pressure pumping and drilling segments. He added that the segments are facing volatility and uncertainty which led to delays in capital expenditures. The CEO indicated that the company has made progress in other segments such as power generation, midstream, and marine which will enhance the diversification of the company’s business.

Q2 Milestones

Revenues continued to be affected negatively because of delays in orders from customers in the Gas &Oil category because of downward market trends. The company has indicated that although they are optimistic that the orders will finally be received it is still hard to predict when that will happen.

Puradyn has indicated that it is almost completing trials by two leading customers in the midstream segment. This will lead to company receiving orders towards the end of the year. It could also open the company’s product viability throughout the segment. The company secured a major inland marine customer who will begin equipping the whole fleet in Q3. Puradyn also succeeded in securing a leading government contractor responsible for maintenance of generators at US military operations

This is Why Koios is a Leader and Continues with Massive Growth

Ok… We have to start to get serious about a proven industry that’s in the beginning stages of making an extreme change…

Remember about a little over a decade ago when energy drinks exploded overnight and we were seeing new energy drinks coupled with strong marketing seemingly popping up out of nowhere?

You had your Red Bull girls, your Monsters, your Rockstars, your Amps, and a number of other little ones all touting “explosive energy in a can brah!” Whether it was the addictive nature of 200mgs of caffeine and 50gs of sugar per can, the quality marketing, or simply the fact that the big soda staples have been feeding us the same flavord beverage since the early 1900’s, no one could deny that these new drinks were something that the buying population wanted.

These drinks are more expensive than the average carbonated beverage but that didn’t stop consumers from purchasing because these consumers were already looking for a beverage in the healthier direction and boy did these new energy drinks try to market themselves as the new healthier alternative.

Well, ten years later, it’s 2019, the money for the marketing gimmicks has dried up, the taste never improved, and most importantly, the customers have gotten smarter.

The problem for the energy drink industry is that they didn’t deliver on what was potentially a huge chunk of the market. Further, their drinks were essentially sugar and caffeine in a can. They were marketed as being healthier than a can of coke but they weren’t. In many cases, they were worse. And once the consumers figured it out, they left in droves.

But there’s no question that people still want energy in hand. Just go to any Starbucks and see consumer after consumer suck down cup after cup of coffee just to get a hit of it.

Consumers just demanded that the product be healthy, light on the caffeine and sugar, offer brain support, and all around be a drink that boosts performance. – You know, kind of what the energy drinks of the previous decade marketed? – Is that too much to ask?…

Perhaps in 2009, but not anymore…

Enter the world of biohacking and nootropics, which is a class of natural occurring ingredients that switch on your brain and boost mental performance.

Nootropics are supplements that purport to make us smarter.

Natural nootropics include ingredients like artichoke extract, grape seed extract, ginseng, kava kava, lemon balm, Rhodiola rosea, St John’s wort, yerba mate, caffeine, green tea — substances the U.S. Food and Drug Administration has approved as dietary supplements and classifies as GRAS (generally regarded as safe).

Natural nootropics also include synthetic additives such as choline, griffonia seed extract, theanine, acetyl l-carnitine, B group vitamins, iodine and magnesium just to name a few.

Followers of the nootropic movement, myself included, are adamant of the positive effects. They claim regular consumption could lead to consumers being more alert, getting a boost in memory, increased focus, more creativity, motivation, improved cognitive skills and a better overall outlook on life.

What’s more is that this industry is in the process of pivoting directly into the beverage market at almost exactly the perfect time as a slew of new beverages that contain various combinations of nootropics designed to enhance brain function, with added ingredients that have no jittery side-effects, and, (hint hint) our favorite play has even started the process of adding CBD to further enhance the health experience.

The point is, these beverages are the real deal. They’re everything that the average consumer of more high-end beverages has been hoping for and I believe that these nootropic functional beverages are the future of the entire beverage industry.

Because the fact of the matter is this; beverage companies won’t survive if they ignore the evolution of the consumer for much longer. Consumers are more educated in their dietary choices today and they’ve been on the lookout for healthier beverage alternatives to the high-fructose corn syrup, artificial ingredients, and artificial colors of the beverages of the past.

I mean, what the hell are you putting an ingredient called: Yellow Number 5 into a beverage and actually expect people to drink that trash?

The point here is that this ongoing trend shows us that the beverage industry is ripe for a category killer.

In fact, according to BevNet, the beverage industry has experienced half a decade-long decline in sales of traditional sugary soft drinks, forcing major beverage companies to look at other beverage companies in search of acquisition to replace their lagging sales.

And we’ve got one such nootropic beverage company at the top of our watch list that has our near complete attention because we believe it to be the one that has the best opportunity to be a category killer in the market.

The company’s name is Koios Beverage Corp. trading on the OTC under the ticker: KBEVF.

Koios Beverage Corp. develops, manufactures, markets, and distributes nutritional supplements and organic beverages in the United States. It also provides cannabis-infused beverages. As of May 31, 2018, the company had a distribution network of approximately 4,300 retail locations in the United States. It also distributes its products through its website, as well as through other websites.

Due to the functional properties of their nootropic drinks, their lack of the caffeine-crash, and honest to goodness incredible taste, I believe that Koios could become the next big thing in the functional beverage market and eventually displace the old and outdated energy drinks of yesteryear and take the lead in future sales.

They’re already in large retail chain stores such as Walmart and GNC and already have a strong presence on Amazon. They’ve achieved distribution in a total of more than 4,300 stores in less than one year, including 2,910 GNC locations and 1,094 Walmart locations across the United States.

But what truly sets Koios apart from any other functional beverage drink is their creativity and open willingness to invent something truly unique. As of July 19, 2019, through its subsidiary, Cannavated Beverage Corp, Koios has completed development of its CBD-Enhanced functional and began test batch production.

Koios is the real deal and I personally love their drinks. Let’s dive deeper into Koios by going over its key catalysts.

Key Catalysts:

The company is making big moves in multiple explosive industries:
- The global nootropic market is booming. In 2015, the market was valued at $1.35 billion and is expected to reach over $6 billion by 2024.
  - The market is expanding at a CAGR of 17.9% from 2016 to 2024 according to globalnewswire.com.
- Koios is also utilizing its subsidiary, Cannavated Beverage Corp by becoming the first “nootropic” beverages enhanced with CBD cannabidiol molecules.
  - The CBD market is expected to hit $22Billion by 2022 according to inc.com.
- In 2016, while carbonated soft drinks were in the middle of a five-year decline, natural and functional beverages should expect to see a 40 percent dollar growth in the industry according to BevNet.
Aggressive Expansion
- As of early 2019, Koios announced that it signed a vendor agreement with Walmart Inc., and has since been supplying Koios Beverages to 1,094 Walmart locations across the US.
- Koios also secured an agreement in early 2019 with GNC. According to the agreement, their beverages are now available for purchase in approximately 2,700 GNC retail stores across the US.
- The company also announced that production is on the rise as the company is currently working to produce 1,000,000 printed KOIOS cans as production levels ramp up to meet the company’s current demands.
Excellent Recent News
- Koios has completed development of its CBD-Enhanced functional and began test batch production on July 19, 2019.
- Koios also recently provided a very positive corporate update, including:
  - Strong sales numbers
  - Revamped website
  - And the much anticipated Fit Soda launch date, announced above as July 19, 2019.
  - Get the full report here: https://finance.yahoo.com/news/koios-provides-mid-2019-corporate-100000206.html

The Nootropic Market & Functional Beverages

According to the latest report published by Credence Research, Inc. “Nootropics Market – Growth, Future Prospects and Competitive Analysis, 2016-2024,” the global nootropics market was valued at USD 1,346.5 Mn in 2015, and is expected to reach USD 6,059.4 Mn by 2024, expanding at a CAGR of 17.9% from 2016 to 2024.

With expansion projected like that, this is a market that’s worth our attention and we ought to be in the know on all the recent developments in this market as well. This is where Nootropic beverages come in because they are the cutting edge in the Nootropics market.

Nootropic beverages are under the umbrella of the booming multi-billion dollar category of “Functional Beverages.”

A functional beverage is a non-alcoholic drink which provides specific health benefits and contains non-traditional ingredients like minerals, vitamins, herbs, amino acids or added raw fruits.

Basically, it’s a drink augmented with nutrients and/or supplements in order to convey a health benefit to the consumer. Examples of functional beverages include sports and performance drinks, ready to drink (RTD) teas, and nootropic beverages sometimes known as ‘smart drinks’.

Functional drinks are typically more expensive than carbonated beverages due to their shift away from unhealthy and artificial ingredients. However, increasing health awareness in many countries is encouraging consumers to shift from beverages loaded with high-fructose corn syrup, artificial flavors and artificial colors to healthier alternatives in the functional drinks segment, which is expected to boost the demand for the product.

Fit Soda: Koios CBD Enhanced Functional Beverage

As of last week, Koios to Complete Development of CBD-Enhanced Functional Beverage Line: Test Batch Production to Begin on Friday, July 19, 2019 – Get the Full Report Here: https://finance.yahoo.com/news/koios-complete-development-cbd-enhanced-100000708.html

In a press release dated September 4, 2018 , the Company announced its plans to release a functional beverage, which would be infused with CBD to enhance the beverage’s effects and last week test batch production began.

Koios will leverage its existing relationship with Colorado based Keef Brands in the development of this product, with Keef Brands to supply crystalized, water-soluble CBD which will be added to Koios’ existing Fit SodaTM line of functional beverages.

From the corporate update: The Fit SodaTM beverage product will be produced for nationwide distribution beginning Friday, July 19, 2019 . Koios has received interest in distributing Fit SodaTM from distributors and direct-to-store delivery companies from across the United States. Fit SodaTM will be available in 400 retail stores across the United States no later than the end of September, 2019.

For those of you who don’t know why adding CBD to a functional beverage is such a big deal, check this out: CBD is the non-psychoactive counterpart in cannabis that’s regularly used to treat inflammation, pain, anxiety and epileptic seizures.

The addition of CBD to Koios’ proprietary stack of nutrients, amino acids, and electrolytes in its Fit SodaTM line of beverages is expected to improve the product’s already impressive effects.

Pending completion of further testing, the Company also plans to integrate CBD into its KOIOS beverage lineup at a later date. When the proposed beverage is released, Fit SodaTM will be available both with and without CBD.

On Friday, July 19, 2019 , Koios started production of several test batches of its Fit SodaTM product with crystallized CBD supplied by Keef Brands. Upon completion of this production, the Company will be distributing the products from the test batch to select existing clients for trial purposes.

Feedback derived from these trials will be utilized to further develop the proposed CBD beverage and prepare it for commercial production and distribution under the Fit SodaTM banner.

Large-scale distribution of CBD-enhanced Fit SodaTM will be contemplated by Koios based on feedback that the Company receives from the test batches being produced that began last week.

We are extremely excited to find out how the large-scale distribution works out and will make sure to update you all when it’s released by the company.

More About Koios

For our purposes, the key to the company’s success has been their anti-reliance on caffeine and their focus on ingredients that increase clarity and focus of the mind.

Koios enhances focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity, and creates all day mental clarity and energy, without using large amounts of stimulants.

And the science is starting to ramp up fast. Just a few months ago, Koios started clinical trials in Denver to prove the testimonials right. “Enhances cognition.” Imagine seeing that on a can in Walmart!

Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy.

The company produces Koios in the following formulations:

Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
Vegan-friendly capsules;
Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios developed a proprietary nootropic formula that has been shown to enhance brain function including mental focus, memory, and concentration.

Its formula includes superfoods such as lion’s mane mushroom, which contains bioactive substances with beneficial effects on the body, brain, heart, and gut. The Company produces the formula as a line of healthy, organic beverages and drink powders.

Koios has a distribution network of retail locations across the United States including Walmart, GNC and Max Muscle. Together these distributors represent more than 4,300 locations, from sports nutrition stores to natural grocery chains.

Koios also contains the following ingredients, among others:

Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
Ciwujia or Siberian ginseng Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that this herb has clear positive effects on endurance.

The company’s products can be found online at https://www.mentaltitan.com and in stores, both across the United States and internationally, via a continuously growing distribution network.

Disclaimer :

This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on KBEV (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.

Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.

Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.

Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.

TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.

CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.

By using Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.

The website contains links to other related World Wide Web Internet sites and resources. Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does Small Cap Exclusive endorse nor is Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.

You agree to indemnify and hold Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Koios Beverage Corp. Small Cap Exclusive has been hired by Koios Beverage Corp. for a period beginning on May 1, 2018 to publicly disseminate information about (KBEV) via website and email. We have been compensated $558,000. We will update any changes to our compensation. We own zero shares of (KBEV).

Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. Koios Beverage Corp. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.

The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.

We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.

The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.

We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.

There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.

We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.

We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.

If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.

The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.

The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.

You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.

When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.

The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.

We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.

If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.

If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.

No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.

Small Cap Exclusive, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

Koios to Complete Development of CBD-Enhanced Functional Beverage Line

Following the Company’s September 4, 2018 announcement of plans to release a functional beverage infused with CBD, Koios has resumed development with test batch production set to begin tomorrow. The CBD cannabinoid will be added to Koios’ “Fit Soda^TM” line of functional beverages, as a method of enhancing the beverage’s effects. The Company temporarily suspended its development of a CBD-enhanced functional beverage in Q4 of 2018, citing a management decision to focus on existing product lines and retailer relationships, as well as an uncertain landscape with respect to CBD’s legality and its public perception. Koios will continue its working relationship with Colorado-based Keef Brands, who will supply crystalized water-soluble CBD for the proposed beverage.

VANCOUVER, July 18, 2019 – Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that it has made several key developments with respect to its proposed line of functional beverages containing broad-spectrum hemp extract cannabidiol (“CBD”). In a press release dated September 4, 2018, the Company announced its plans to release a functional beverage, which would be infused with CBD to enhance the beverage’s effects. Koios will leverage its existing relationship with Colorado-based Keef Brands in the development of this product, with Keef Brands to supply crystalized, water-soluble CBD which will be added to Koios’ existing Fit Soda^TM line of functional beverages. Starting tomorrow, the Company and Keef Brands will produce several test batches of the proposed CBD beverage, with user trials to begin shortly afterward.

[thrive_leads id=’8530′]

CBD is a cannabinoid produced in the cannabis plant, and it is regularly used to treat inflammation, pain, anxiety and epileptic seizures. CBD differs from the tetrahydrocannabinol (“THC”) cannabinoid, in that it is not psychoactive and it does not create the same sensations commonly desired by users of cannabis as a recreational drug. The addition of CBD to Koios’ proprietary stack of nutrients, amino acids, and electrolytes in its Fit Soda^TM line of beverages is expected to improve the product’s effects. Pending completion of further testing, the Company also plans to integrate CBD into its eponymous KOIOS beverage lineup at a later date. When the proposed beverage is released, Fit Soda will be available both with and without CBD.

Koios had elected to defer the finalization of the proposed CBD beverage from its original target of October 2018 based on a decision to place the Company’s full focus on its existing KOIOS and Fit Soda^TM beverage lineups. With overwhelming success of these two product lines being distributed through some of the world’s largest retailers, the Company’s management deemed it to be in Koios’ best interests to capitalize on this existing demand which generates the most volume, profit and opportunity. Moreover, the overall perception of CBD from legal and scientific perspectives had been unclear for some time, creating a suboptimal landscape for products containing CBD. As a result, Koios has taken a passive approach to the introduction of CBD to its beverages, both in anticipation of the overall CBD landscape improving, as well as for taking the time to observe any “growing pains” experienced by other manufacturers who have sought to incorporate CBD into their product offerings, from which Koios has gleaned insight for solidifying its CBD product strategy.

On Friday, July 19, 2019, Koios will start production of several test batches of its Fit Soda^TM product with crystallized CBD supplied by Keef Brands. Upon completion of this production, the Company will be distributing the products from the test batch to select existing clients for trial purposes. Additionally, Koios has consumer trials planned with individuals in its local community. Feedback derived from these trials will be utilized to further develop the proposed CBD beverage and prepare it for commercial production and distribution under the Fit Soda^TM banner. The water-soluble CBD crystals supplied through Keef Brands have shown consistent potency and efficacy results in Keef’s internal evaluation efforts of numerous water-soluble CBD solutions over the past year.

Large-scale distribution of CBD-enhanced Fit Soda^TM will be contemplated by Koios based on feedback that the Company receives from the test batches being produced beginning tomorrow. Developments with respect to this large-scale distribution, including interest received from retail vendors, will be announced in a future press release.

Keef Brands Chief Operating Officer Travis Tharp commented, “We are very pleased to be growing our relationship with Koios in the development of a CBD-enhanced functional beverage product. As cannabis products continue to have a greater scope of use in a variety of industries, we are thrilled to have first-hand exposure to a novel use of this type of ingredient in beverages. These are very exciting times for both Keef Brands and Koios, and we are looking forward to the outcomes of our test batches.”

Koios Chief Executive Officer Chris Miller added, “I believe we made the right choice with respect to waiting until now to finalize our development of a CBD-enhanced functional beverage. Between an ambiguous legal landscape for CBD, as well as an unbelievable amount of pseudoscience and false claims about this cannabinoid, last year simply was not the right time for us to finalize such a product or bring it to market. By holding off, we have been able to put our full focus on our existing products and relationships with large-scale retailers. Additionally, it gave us the opportunity to observe others’ successes and failures in developing or releasing CBD products, from which we are learning, for when we ultimately release our beverages with CBD. We are thankful for being able to continue working with Keef Brands as such a highly-respected firm in the beverages space, and we are eagerly anticipating positive results from the test batch trials.”

About Koios Beverage Corp.

The Company is an emerging functional beverage company which has an available distribution network of more than 4,300 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable retailers in the United States, including GNC, Walmart Inc., and Wishing-U-Well. Together these retailers represent over 50,000 brick and mortar locations across the United States from sports nutrition stores to large natural grocery chains. Through its partnership with Wishing-U-Well, Koios also enjoys a significant presence online, including being an Amazon choice product.

Koios is also the sole owner of Cannavated Beverage Corp., a subsidiary that develops beverage products and formulas for the growing CBD market. Koios uses a proprietary blend of nootropics and natural, organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products have been shown to enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios produces one of the only drinks in the world infused with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for more significant brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.koiosbeveragecorp.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: statements with respect to the growth and size of the functional beverage and CBD infused beverage markets; the statement that CBD infused beverage markets will become legal in the US and Canada; statements with respect to our relationship with Keef Brands to produce a CBD infused line of Fit Soda^TM; statements with respect to the distribution from the test batch to select existing clients for trial purposes and consumer trials planned with individuals in the local community; and statements regarding the business of the Company. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the functional and CBD infused beverage markets; (iii) consumer acceptance and adoption of functional beverages and CBD infused beverages as compared to other beverages; and (iv) changes which may affect the legalization of markets in the US and Canada; and (v) other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither Koios nor Keef Brands have conducted any scientific studies on the effects of Koios’ products or the water-soluble CBD which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’ products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’ products on an individual’s health and wellbeing.